Canaccord Genuity Group Increases BioNTech (NASDAQ:BNTX) Price Target to $171.44

BioNTech (NASDAQ:BNTX) had its price target increased by Canaccord Genuity Group from $171.00 to $171.44 in a report published on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Other analysts also recently issued reports about the stock. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and lifted their price target for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. UBS Group boosted their price objective on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Finally, Berenberg Bank assumed coverage on BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Stock Performance

Shares of BNTX stock opened at $118.39 on Wednesday. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market capitalization of $28.38 billion, a price-to-earnings ratio of -56.38 and a beta of 0.26. The business has a 50 day simple moving average of $113.81 and a 200 day simple moving average of $98.68.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the prior year, the business posted $0.73 earnings per share. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. On average, equities research analysts anticipate that BioNTech will post -3.68 EPS for the current year.

Institutional Trading of BioNTech

A number of hedge funds have recently bought and sold shares of BNTX. GAMMA Investing LLC raised its holdings in shares of BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after acquiring an additional 238 shares during the period. EverSource Wealth Advisors LLC raised its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the period. Planning Capital Management Corp lifted its holdings in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. boosted its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. Finally, Daiwa Securities Group Inc. grew its holdings in shares of BioNTech by 430.3% during the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after buying an additional 1,562 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.